See more : Super Hi International Holding Ltd. (9658.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Empower Clinics Inc. (EPWCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Empower Clinics Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Concrete Pumping Holdings, Inc. (BBCP) Income Statement Analysis – Financial Results
- Daiki Aluminium Industry Co., Ltd. (5702.T) Income Statement Analysis – Financial Results
- Remak-Energomontaz S.A. (RMK.WA) Income Statement Analysis – Financial Results
- Allurion Technologies Inc. (ALUR) Income Statement Analysis – Financial Results
- ShinWon Corporation (009270.KS) Income Statement Analysis – Financial Results
Empower Clinics Inc. (EPWCF)
About Empower Clinics Inc.
Empower Clinics Inc., an integrated healthcare company, provides body and mind wellness services for patients through digital and telemedicine care, and medical diagnostics laboratories in the United States and Canada. The company operates a pipeline of 33 clinics in Alberta, British Columbia, and New Brunswick. It has a strategic alliance with SoLVBL Solutions Inc. to develop a program for data security in diagnostic testing. Empower Clinics Inc. is based in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.66M | 4.37M | 3.21M | 2.03M | 1.09M | 1.56M | 2.13K | 0.00 | 17.00K | 17.00K | 1.89M | 1.32M | 912.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.69M | 3.02M | 1.19M | 826.28K | 417.05K | 768.90K | 718.11 | 0.00 | 0.00 | 8.64M | 12.25M | 4.76M | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.97M | 1.35M | 2.02M | 1.21M | 674.34K | 792.35K | 1.42K | 0.00 | 17.00K | -8.62M | -10.36M | -3.44M | -434.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 42.22% | 30.87% | 62.81% | 59.33% | 61.79% | 50.75% | 66.36% | 0.00% | 100.00% | -50,729.41% | -548.54% | -259.71% | -47.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 962.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.20M | 4.60M | 3.74M | 3.80M | 4.50M | 113.00K | 268.00K | 349.00K | 93.00K | 2.29M | 2.31M | 4.89M | 1.97M | 1.37M | 247.64K | 90.64K | 68.05K | 17.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 652.13K | 751.51K | 1.03M | 313.87K | 306.80K | 171.81 | 60.35 | 0.00 | 0.00 | 0.00 | 0.00 | 401.00K | 0.00 | 4.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.75M | 5.35M | 4.77M | 4.12M | 4.81M | 113.00K | 268.00K | 349.00K | 93.00K | 2.29M | 2.31M | 5.29M | 1.97M | 1.38M | 247.64K | 90.64K | 68.05K | 17.45K | 34.47K | 73.49K | 140.33K | 178.59K | 264.37K | 43.79K |
| Other Expenses | 173.07K | 1.41M | 850.85K | 604.31K | 829.43K | 0.00 | 0.00 | 23.02K | 469.00K | 765.00K | 3.52M | 4.84M | 1.22K | 5.88K | 37.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 730.76K | 856.23K | 64.85K |
| Operating Expenses | 6.92M | 6.75M | 5.62M | 4.72M | 4.98M | 113.00K | 268.00K | 349.00K | 562.00K | 3.06M | 5.83M | 5.29M | 2.94M | 1.38M | 285.18K | 90.64K | 68.05K | 17.45K | 34.47K | 73.49K | 140.33K | 909.34K | 1.12M | 108.63K |
| Cost & Expenses | 9.62M | 9.78M | 6.81M | 5.55M | 5.40M | 113.00K | 268.00K | 349.00K | 562.00K | 3.06M | 5.83M | 10.05M | 2.94M | 1.38M | 285.18K | 90.64K | 68.05K | 17.45K | 34.47K | 73.49K | 140.33K | 909.34K | 1.12M | 108.63K |
| Interest Income | 911.23K | 185.41K | 7.57K | 4.98K | 0.00 | 6.00K | 0.00 | 0.00 | 0.00 | 3.03M | 2.48M | 43.00K | 398.00 | 0.00 | 40.06K | 0.00 | 31.87K | 360.00 | 0.00 | 1.29K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.55M | 185.41K | 539.41K | 355.05K | 367.90K | 0.00 | 0.00 | 0.00 | 0.00 | 30.00K | 745.00K | 109.00K | 0.00 | 0.00 | -285.18K | -90.64K | -35.40K | -18.75K | -64.09K | -341.81K | -137.40K | -893.77K | -1.11M | -108.63K |
| Depreciation & Amortization | 205.04K | 535.12K | 188.38K | 334.66K | 117.18K | 107.09K | 106.17K | 55.00K | 45.00K | 88.00K | 96.00K | 80.00K | 1.22K | 14.71K | 2.52K | 65.31K | 1.23K | 415.00 | 565.00 | 772.00 | 1.06K | 1.44K | 410.00 | 11.47K |
| EBITDA | -1.09M | -30.74M | -16.84M | -3.70M | -3.13M | -2.23M | -212.41K | -247.76K | 743.78K | -5.39M | -4.35M | -9.66M | -2.02M | -1.50M | -268.33K | 0.00 | -36.17K | -19.35K | -66.53K | -72.72K | -138.34K | -907.91K | -1.12M | -108.63K |
| EBITDA Ratio | -23.35% | -105.37% | -100.14% | -140.57% | -307.54% | -9.67% | -15,036.14% | 0.00% | -10,670.59% | 447.06% | -72.42% | -650.26% | -222.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.95M | -5.41M | -3.61M | -3.52M | -4.31M | -113.00K | -268.00K | -349.00K | 772.00K | -8.64M | -12.25M | -9.95M | -2.03M | -1.38M | -285.18K | -90.64K | -68.05K | -17.45K | -34.47K | -73.49K | -140.33K | -893.77K | -1.11M | -108.63K |
| Operating Income Ratio | -106.28% | -123.75% | -112.35% | -173.02% | -394.85% | -7.24% | -12,553.53% | 0.00% | 4,541.18% | -50,829.41% | -648.54% | -752.23% | -222.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.11M | -26.29M | -13.09M | -163.45K | 519.46K | -3.11M | -1.00K | 49.74K | 1.27M | -2.27M | -6.06M | -66.00K | 398.00 | 14.71K | 2.52K | 65.31K | 31.87K | -1.33K | -29.62K | -268.32K | 2.93K | 0.00 | 0.00 | 11.47K |
| Income Before Tax | -2.84M | -31.74M | -17.07M | -4.30M | -3.79M | -75.00K | -215.00K | -269.00K | 735.00K | -5.64M | -10.52M | -10.02M | -2.03M | -1.37M | -282.66K | -25.33K | -36.17K | -18.77K | -64.09K | -341.81K | -137.40K | -893.77K | -1.11M | -97.17K |
| Income Before Tax Ratio | -61.00% | -726.41% | -531.79% | -211.74% | -347.26% | -4.80% | -10,070.93% | 0.00% | 4,323.53% | -33,200.00% | -556.70% | -757.22% | -222.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 165.00 | 968.67K | 542.21K | 812.18K | -519.46K | -38.00K | -53.00K | -55.00K | 37.00K | 2.61M | 41.00K | 33.00K | 6.22K | 1.37M | 282.66K | 25.33K | 36.17K | 18.77K | 64.09K | 341.81K | 137.40K | 893.77K | 1.11M | 97.17K |
| Net Income | -2.83K | -32.70M | -17.61M | -5.11M | -3.79M | -75.00K | -215.00K | -269.00K | 735.00K | -5.64M | -8.55M | -10.05M | -2.03M | -1.37M | -282.66K | -25.33K | -36.17K | -18.77K | -64.09K | -341.81K | -137.40K | -893.77K | -1.11M | -97.17K |
| Net Income Ratio | -0.06% | -748.58% | -548.69% | -251.72% | -347.26% | -4.80% | -10,070.93% | 0.00% | 4,323.53% | -33,200.00% | -452.83% | -759.71% | -222.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.50 | -0.48 | -0.22 | -0.28 | -0.02 | -0.06 | -0.09 | 0.30 | -2.34 | -4.83 | -7.55 | -2.43 | -3.89 | -0.91 | -0.08 | -0.13 | -0.08 | -0.29 | -1.44 | -0.53 | -3.75 | -5.25 | -0.75 |
| EPS Diluted | -0.04 | -0.50 | -0.48 | -0.22 | -0.28 | -0.02 | -0.06 | -0.09 | 0.30 | -2.34 | -4.83 | -7.55 | -2.43 | -3.89 | -0.91 | -0.08 | -0.13 | -0.08 | -0.29 | -1.44 | -0.53 | -3.75 | -5.25 | -0.75 |
| Weighted Avg Shares Out | 70.21M | 65.60M | 36.47M | 23.46M | 13.33M | 3.42M | 3.42M | 3.09M | 2.43M | 2.41M | 1.77M | 1.33M | 835.20K | 352.20K | 309.33K | 309.33K | 268.96K | 221.33K | 221.33K | 237.88K | 261.33K | 238.34K | 210.76K | 129.55K |
| Weighted Avg Shares Out (Dil) | 70.21M | 65.60M | 36.47M | 23.46M | 13.33M | 3.42M | 3.42M | 3.09M | 2.43M | 2.41M | 1.77M | 1.33M | 835.20K | 352.20K | 309.33K | 309.33K | 268.96K | 221.33K | 221.33K | 237.88K | 261.33K | 238.34K | 210.76K | 129.55K |
Empower Clinics commences process to explore and evaluate strategic options
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value with the engagement of Haywood Securities Inc as the company's strategic financial advisor. "Maximizing shareholder value is a...
Empower Clinics advances partnership to launch US clinical trial management services
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) has said its previously announced LOI (letter of intent) to create and operate a Dallas-based Site Management Organization (SMO) has accelerated in the first 30 days with the official formation of a joint venture (JV) company...
Empower Clinics ends Q4 2022 with $193,144 in cash; continues to focus on clinical trial services
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) has said it held $193,144 in cash at end-2022 as it announced its interim results for the fourth quarter to 31 December 2022. The company has previously said it is changing its fiscal year end...
Empower Clinics partners with nuclear medicine specialist to launch US clinical trial management services
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said it has entered into a letter of intent (LOI) with Dr Bharat Mocherla, a Nuclear Medicine Specialist in Las Vegas, Nevada, with over 15 years of experience in the medical and clinical trials field, to...
Empower Clinics announces partnership with Fobi AI unit to elevate investor relations with digital, mobile and personalized engagement
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) told investors it signed a deal with PulseIR, a wholly-owned subsidiary of Fobi AI (TSX-V:FOBI, OTCQB:FOBIF), to deliver personalized, automated, and data-driven mobile investor relations (IR) solutions to existing and potential shareholders. The company explained...
Empower Clinics says subsidiary MediSure's diabetes test strips get OK for government programs
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) said its subsidiary MediSure Canada's next-generation diabetes testing solutions - MediSure Empower Test Strips - have been approved to be part of the formularies of four government jurisdictions, departments and programs. The four government entities...
Empower Clinics announces an offering of units at a price of 3 cents each for aggregate gross proceeds of between $2M and $5M
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) has announced an offering of a minimum of 66,666,666 and a maximum of 166,666,667 units of the company at a price of 3 cents each for aggregate gross proceeds of between $2 million and $5...
Empower Clinics consolidates three medical clinics to focus on flagship Etobicoke integrated medical clinic
Empower Clinics Inc has announced that it is consolidating three of its The Medi-Collective (TMC) medical clinics, with resources to be focused into its flagship Etobicoke - 3590 Lakeshore Blvd West - integrated medical clinic. The three affected clinics are...
Empower Clinics says MediSure Laboratory signs laboratory services agreement with Alp MedTech AG
Empower Clinics Inc. (CSE:EPW, OTCQB:EPWCF) announced that its MediSure Laboratory has signed a laboratory services agreement with Alp MedTech AG. This agreement follows the partnership announced on December 19t, 2022, between Empower and Alp MedTech - the authorized representative of Atlas Medical...
Empower Clinics taps Zeifmans LLP as new auditor as it boosts accounting and financial controls
Empower Clinics Inc, one of the largest operators of medical health and wellness centers in the US, revealed that it had appointed Zeifmans LLP as its new auditor from December 20, 2022, to strengthen its accounting and financial controls. The...
Source: https://incomestatements.info
Category: Stock Reports